Technology transfer is crucial for converting new innovations into commercially viable products that can be produced reliably and consistently, at scale, and across manufacturing sites and geographic regions. Historically, technology transfer was primarily focused on ensuring successful knowledge and process transfer between sites and manufacturing stages.1 Today, sponsors expect far more: comparable product quality, predictable timelines, commercial readiness, supply reliability, and competitive performance at speed.

Most technology transfers follow a familiar process, but outcomes differ. Some programs progress smoothly from development into commercial supply, while others encounter delays, unexpected process behaviors, scale-up challenges, or costly post-transfer remediation.

In considering the factors behind smooth versus struggling technology transfers, 4 shifts may explain why some technology transfers stay on track while others struggle. These variations shift the focus from knowledge transfer, comparability, process transfer, and experience-based decisions to risk identification, commercial readiness, value creation, and data-driven decisions (Table 1). In practice, organizations that consistently achieve successful technology transfers are those that identify risks earlier, establish commercial readiness faster, and leverage accumulated process knowledge more effectively.

Early Risk Identification

Technology transfer is often viewed as the movement of documents, data packages, and process descriptions from 1 organization to another. This explains a historical focus on knowledge transfer. However, in today’s increasingly complex biologics industry, the greater challenge is understanding what may still be unknown.

Even comprehensive transfer packages can leave important knowledge gaps. Critical process understanding may reside in development experience, manufacturing history, troubleshooting records, or tacit knowledge held by technical teams. International Council for Harmonisation (ICH) Q10 recognizes that technology transfer extends beyond documentation exchange and requires effective knowledge management and quality risk management to support product realization.1

Successful technology transfer therefore begins with systematic risk identification. Many of the highest-impact risks emerge at the interfaces between process, equipment, materials, facilities, analytical methods, and operations. To address these challenges, a multidimensional risk-assessment approach should be applied to identify gaps that may not be apparent from transfer documentation alone.

Rather than relying solely on transferred information, teams should challenge assumptions through facility-fit assessments, equipment compatibility reviews, analytical bridging strategies, process robustness evaluations, and structured risk-management workflows. Standardized transfer tools, technical risk checklists, equipment databases, and harmonized documentation systems help identify gapsfaster while ensuring critical risks are evaluated consistently.

A case study (Figure 1), in which process issues were successfully and proactively resolved through extensive investigations and targeted process optimization, demonstrated how successful technology transfer is not defined by the absence of risk. Rather, it is defined by the ability to anticipate and manage risk early enough to prevent it from affecting manufacturing performance.

Faster Commercial Readiness

Execution speed is a critical dimension of commercial readiness. Transfer delays can affect process performance qualification readiness, biologics license application timelines, and launch planning. Accelerated technology transfer requires eliminating uncertainty earlier and enabling faster decisions through standardized execution.

While every program presents unique challenges, standardized execution frameworks can significantly compress transfer timelines. Supported by harmonized methodologies, platform-based process knowledge, and globally aligned documentation practices, some transfers have been completed in as little as 3.5 months for commercial manufacturing programs, 50% faster than the industry average.

For example, comparability is essential in technology transfer, but it alone does not guarantee commercial success. As programs advance toward commercial supply, processes frequently transition across scales, equipment platforms, manufacturing sites, and geographic regions. Each transition introduces variables that can affect process performance, operational execution, and supply continuity.

Single-use technologies, for example, are reshaping biologics manufacturing by enabling greater agility, faster deployment, and enhanced operational flexibility throughout the product lifecycle. As organizations continue to expand and optimize their manufacturing networks, seamless transfer between stainless-steel and single-use systems has become an important capability for accelerating commercialization.

Technology transfer teams can apply standardized methodologies, engineering understanding, and accumulated platform knowledge to ensure consistent process performance while capturing the flexibility benefits of modern manufacturing systems. In an example, a biologics program was successfully transferred between manufacturing platforms while maintaining comparable process performance and product quality attributes. The program demonstrates how standardized transfer frameworks, robust process understanding, and platform expertise can translate manufacturing flexibility into faster commercial readiness (Figure 2).

Another urgent license-out program illustrated how, following comprehensive gap analysis and risk assessment, a customized transfer strategy was established within 2 weeks, enabling drug substance delivery only 70 days after vial transfer-in while maintaining high quality and supply continuity.

Commercial readiness also extends beyond a single manufacturing facility. Harmonized technology transfer practices, globally aligned quality systems, dual-sourcing strategies, and integrated product development, manufacturing science and technology, and manufacturing teams help support supply resilience across facilities and regions.

Ultimately, commercial readiness is about demonstrating that a process can run reliably, at scale, on the intended manufacturing platform, within the required timeline, and across a resilient global supply network.

Value Creation

Achieving commercial readiness is not necessarily the end of the technology transfer journey. The next challenge isunlocking greater manufacturing value. For commercial biologics,improvement in productivity, manufacturing efficiency, material utilization, and cost of goods (CoGs) can significantly strengthen long-term competitiveness, even when product quality remains unchanged.

Technology transfer therefore represents the prospect to systematically improve manufacturing performance before commercial execution becomes locked through validation and regulatory filings.

Potential opportunities may include optimizing material consumption, improving manufacturing productivity, increasing process intensity, enhancing batch consistency, and strengthening process control. When these improvements are evaluated and implemented during technology transfer, organizations may achieve measurable long-term manufacturing benefits. Because media, resins, filters, and membranes can represent a significant portion of manufacturing costs,material optimization, load-capacity enhancement, and lifecycle extension can improve economics while maintaining process control and product quality.

Process intensification represents a second lever. Intensified fed-batch and perfusion approaches can increase productivity, improve facility utilization, and expand drug substance output without requiring proportional increases in manufacturing footprint.

For example, compared with conventional fed-batch processes, an ultra-intensified fed-batch platform can deliver 25–85 kg of drug substance per 2000 L batch while reducing CoGs to 15% to 30% of conventional fed-batch levels. Similarly, a intensified perfusion culture platform can deliver up to 40–100 kg of drug substance per 2000 L batch while reducing CoGs to 20% to 50% of conventional fed-batch levels.

A third lever is productivity improvement through deeper process understanding and process control. Advanced monitoring, process analytics, and automated control strategies help identify golden batches, establish optimal operating ranges, and improve consistency and drive for more efficient commercial manufacturing.

A commercial manufacturing program utilizing these levers demonstrated marked improvements in drug substance output and manufacturing costs. Through media optimization and the adoption of a ultra-intensified fed-batch bioprocessing platform, the optimized process delivered approximately 4-fold and 3-fold increases in product titer for 2 antibody molecules while maintaining comparable product quality attributes. The substantial productivity gains and media change translated into a 30% to 40% reduction in CoGs, demonstrating how technology transfer can serve not only as a pathway to commercial manufacturing, but also as an opportunity to enhance long-term process economics and manufacturing competitiveness (Figure 3).

Data-Driven Decisions

As biologics become increasingly complex, technology transfer teams are facing a new challenge: how to convert growing volumes of process data into actionable decisions.

Traditionally, critical information remained fragmented across manufacturing systems, analytical platforms, and process reports. Today, digital technologies are creating a more integrated view of process performance, enabling teams to identify trends earlier, evaluate potential outcomes before implementation, and accelerate decision making throughout technology transfer and commercialization.

One emerging application is the use of digital-twin technologies to improve process understanding and control. By combining process data, predictive analytics, and mechanistic modeling, these approaches can help evaluate process performance, assess potential risks, and support decision-making before changes are implemented at manufacturing scale. For example, a digital twin platform (eg, PatroLab, WuXi Biologics) integrates in-line sensor data, Raman spectroscopy, manufacturing datasets, process models, and simulation capabilities into a unified digital ecosystem. The platform supports real-time monitoring of more than 40 in-process parameters and quality attributes while enabling in silico process simulation.

Digital tools also provide visibility into how a process is evolving during execution. Predictive algorithms can monitor indicators such as viable cell density, glucose consumption, lactate accumulation, and product titer, helping teams recognize abnormal trends earlier and respond proactively.

Digital technologies are also increasingly being applied to facility-fit assessments, scale-up evaluations, and technology transfer planning. Increasingly, the most successful organizations will combine scientific expertise with digital intelligence, allowing the move from reactive troubleshooting toward predictive, data-driven decision-making.

Looking Ahead

Comparability, repeatability, and robustness remain the foundations of successful technology transfer, but in today's biologics industry, they are no longer enough.

Technology transfer has evolved from an operational handover to a strategic enabler of commercialization. Sponsors increasingly expect technology transfer toaccelerate commercial readiness, improve manufacturing economics, and strengthen long-term competitive advantages.

Organizations that consistently achieve these outcomes are not necessarily those executing more transfer activities. They are the ones that anticipate risks earlier, establish commercial readiness faster, create greater manufacturing value, and use digital intelligence to support better decisions.

In this new paradigm, technology transfer is no longermeasured by how effectively knowledge is transferred, but by how effectively that knowledge is transformed into a real commercial success.

References

1. Q10 Pharmaceutical Quality System. ICH. 2008.

About the Author

Sherry Gu, PhD, is executive vice president, chief technology officer, and chief client officer of WuXi Biologics.